2023년 11월 26일 13:59

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats

Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO® (active in ...

제약반려동물연구개발

2023년 11월 23일 09:50

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company ...

제약생명공학인수 매각

2023년 11월 5일 10:20

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The re ...

제약연구개발

2023년 10월 27일 17:27

Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Fo ...

제약수상

2023년 10월 9일 15:05

Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and without Diabetes, Cardiovascular Disease and Chronic Kidney Disease

Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also know ...

제약연구개발

2023년 10월 3일 11:27

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable ear ...

제약의료와 병원제휴

2023년 9월 14일 17:18

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduc ...

제약환경 보전사회공헌

2023년 8월 1일 16:24

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Healt ...

제약실적

2023년 7월 26일 10:45

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),[8] Boehringer Inge ...

제약연구개발

2023년 7월 4일 16:25

Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial

Today, at the 25th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing ...

제약의료와 병원조사분석

2023년 6월 25일 13:26

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also ...

제약조사분석

2023년 6월 25일 10:56

Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardi ...

제약연구개발

2023년 5월 10일 17:22

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss a ...

제약의료와 병원조사분석

2023년 5월 10일 15:40

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Pha ...

제약의료와 병원연구개발

2023년 5월 3일 14:00

SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares

Boehringer Ingelheim announced today that spesolimab (marketed as SPEVIGO®) received Breakthrough Therapy Designation (BTD) as an investigational ...

제약연구개발

2023년 3월 29일 17:16

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, whi ...

제약실적

2023년 1월 30일 17:30

Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares

EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flar ...

제약의료와 병원조사분석

2023년 1월 18일 09:20

Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023

The Top Employers Institute awarded Boehringer Ingelheim for the third year in succession a “Global Top Employer”, one of the world’s 15 best empl ...

제약노동수상

2023년 1월 10일 09:55

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and ...

제약생명공학제휴

2022년 12월 21일 09:45

Boehringer Ingelheim announces appointments to Board of Managing Directors

Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors ...

제약인사

2022년 12월 20일 10:05

Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a ...

제약의료와 병원제휴

2022년 12월 14일 14:25

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for G ...

제약의료와 병원연구개발

2022년 12월 8일 09:40

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average ...

제약의료와 병원조사분석

2022년 11월 7일 11:50

Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living w ...

제약의료와 병원조사분석

2022년 10월 21일 10:40

University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelhe ...

제약의학사업 확장

2022년 10월 21일 10:40

베링거인겔하임-튀빙겐 대학교, AI·데이터과학 연구 개발로 의학 발전 이끌 펠로십 프로그램 발족

유럽 최대 인공지능(AI) 연구 컨소시엄 사이버밸리(Cyber Valley)의 회원인 튀빙겐 대학교(University of Tübingen, 이하 튀빙겐)와 베링거인겔하임(Boehringer Ingelheim)이 전 ...

제약의학사업 확장

2022년 10월 17일 11:35

CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorizatio ...

제약의료와 병원연구개발

2022년 10월 5일 17:15

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim So ...

제약반려동물투자

2022년 9월 6일 10:30

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of n ...

제약의료와 병원조사분석

2022년 9월 2일 16:55

U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psori ...

제약의료와 병원연구개발

2022년 8월 4일 15:45

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first h ...

제약의료와 병원실적

2022년 7월 6일 16:15

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX ...

제약생명공학설립

2022년 6월 15일 09:50

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech c ...

제약생명공학인수 매각

2022년 6월 3일 11:30

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehrin ...

제약의료와 병원계약

2022년 5월 16일 09:30

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was publi ...

제약의료와 병원조사분석

2022년 4월 21일 17:20

Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why ...

제약생명공학신상품

2022년 4월 5일 17:30

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

In 2021, Boehringer Ingelheim again stepped up its annual investments in R&D to a new high in its 137-year history. The company spent 4.1 billion ...

제약실적

2022년 3월 17일 10:15

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will stop early based on a recommendati ...

제약의료와 병원조사분석

2022년 3월 7일 16:40

Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction

The European Commission (EC) has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic ...

제약의료와 병원연구개발

2022년 2월 2일 12:00

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardi ...

제약의료와 병원연구개발

2022년 1월 20일 17:05

Award: Boehringer Ingelheim is Global Top Employer 2022

The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best ...

제약기업 경영수상

2021년 12월 23일 16:30

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 tr ...

제약의료와 병원조사분석

2021년 11월 8일 15:30

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

Empagliflozin reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney f ...

제약의학조사분석

2021년 10월 29일 17:00

Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustu ...

제약의학연구개발

2021년 10월 28일 11:45

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaborati ...

제약의학제휴

2021년 10월 27일 09:40

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license agreement with the aim to investigate novel first-in-class therapies fo ...

제약의학제휴

2021년 10월 19일 17:55

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and th ...

제약생명공학제휴

2021년 9월 23일 16:10

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of ...

제약의학인수 매각

2021년 9월 17일 13:35

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most adv ...

제약조사분석

2021년 9월 10일 15:30

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adu ...

제약연구개발

2021년 8월 30일 10:30

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed an impressive 21 percent relative risk red ...

제약의학조사분석

2021년 8월 3일 17:22

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The com ...

제약실적

2021년 7월 7일 11:25

Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

The EMPEROR-Preserved Phase III trial met its primary endpoint, establishing empagliflozin as the first and only therapy to significantly reduce t ...

제약조사분석

2021년 6월 28일 17:25

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes

The first data from Europe, Israel and East Asia in the EMPRISE real-world evidence study have been presented, revealing a risk reduction in cardi ...

제약조사분석

2021년 6월 22일 11:45

Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction

The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic hear ...

제약사업 확장

2021년 6월 3일 11:55

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has g ...

제약수상

2021년 5월 24일 13:30

CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardi ...

제약사업 확장

2021년 5월 11일 11:50

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to ...

제약의료와 병원사업 확장

2021년 4월 15일 11:51

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Rese ...

제약제휴

2021년 4월 14일 15:50

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual a ...

제약사업 확장

2021년 3월 24일 18:49

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for whi ...

제약실적

2021년 3월 17일 10:40

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on ...

제약제휴

2020년 9월 18일 11:40

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 17019 ...

제약의학제휴

2020년 8월 18일 15:44

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announc ...

제약설립

2020년 3월 16일 09:27

U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of empagliflozin to reduce the risk of kidney ...

제약연구개발

2019년 8월 5일 09:29

Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib foll ...

제약조사분석

2019년 7월 19일 15:22

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with th ...

제약제휴

2019년 4월 15일 16:40

Independent large real-world study comparing NOACs in AF-patients

The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabiga ...

제약조사분석

2019년 4월 15일 16:35

Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme

Boehringer Ingelheim has acquired a minority stake in SoundTalks NV, a Belgian company. SoundTalks NV has developed a digital monitoring tool that ...

제약인수 매각

2019년 4월 15일 09:45

New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® ...

제약조사분석

2017년 9월 8일 10:26

Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments

Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The ...

제약제휴

2017년 8월 21일 16:37

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 2017

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC ...

제약조사분석

2017년 2월 16일 11:28

Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments

Boehringer Ingelheim today announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulm ...

제약사업 확장

2017년 1월 3일 11:40

Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017

Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi’s anim ...

제약인수 매각

2016년 6월 27일 17:36

New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria

New analysis of the INPULSIS® trials show for the first time that disease progression is similar in idiopathic pulmonary fibrosis (IPF) patients i ...

제약조사분석

2016년 6월 27일 15:51

Sanofi and Boehringer Ingelheim Have Reached Definitive Agreements to Swap Sanofi’s Animal Health and Boehringer Ingelheim’s Consumer Healthcare Businesses

Sanofi and Boehringer Ingelheim announced today the signing of contracts to secure the strategic transaction initiated in December 2015 which cons ...

제약제휴

2015년 9월 29일 13:25

ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which ...

제약연구개발

2015년 3월 23일 13:20

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

For non-UK/non-Canadian media only For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*. ...

제약연구개발

2015년 1월 15일 17:45

35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia

The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative trea ...

제약연구개발

 전체 기업